AFM13   Click here for help

GtoPdb Ligand ID: 10067

Synonyms: AFM 13 | AFM-13
Immunopharmacology Ligand
Compound class: Antibody
Comment: AFM13 is a tetravalent bispecific anti-CD30/CD16A tandem diabody that is constructed solely from Fv domains [1]. It is being developed by Affimed as a novel NK cell-engaging immuno-oncology therapeutic for the treatment of CD30-expressing malignancies. AFM13 simultaneously binds CD30 on Hodgkin's lymphoma cells and CD16A (FcγRIIIA) on NK cells, and acts to selectively recruit NK cells immune effector cells to destroy the cancer cells. AFM's mechanism of action differs from that of the anti-CD30 antibody-drug conjugate brentuximab vedotin, and it was found to be active in brentuximab vedotin-refractory patients in Phase 1 trial [2].
Click here for help
Immunopharmacology Comments
AFM13 actively recruits NK cells (by binding CD16A on their surface) selectively to Hodgkin's lymphoma cells (by binding CD30 on these cancer cells) to destroy the cancer cells [1]. AFM13 is a Phase 2 clinical immuno-oncology candidate.
Immunopharmacology Disease
Disease X-Refs Comment References
Lymphoma, Hodgkin, Classic; CHL Disease Ontology: DOID:8567
OMIM: 236000
Phase 2 clinical candidate for relapsed/refractory Hodgkin lymphoma- see NCT02321592